Australia's largest stock trading and investment forum Australia's #1 stock forum

BLT

Click for more information

0.00%

2.6¢ benitec biopharma limited

Ann: BENITEC ABSTRACT ACCEPTED FOR AASLD MEETING, page-18

First 18 Last

Share
Profile

Follow
Dank

2,027 Posts.

22/10/15

15:02

Post #: 16231273
Share

Originally posted by LostOut ↑

seanl,

my (linited) understanding is that there are three stages to the treatment:

1) delivering TT-304 to liver cells using a viral vector,
2) TT-304 then generating the anti-HCV shRNAs designed to fight HCV and
3) those shRNAs actually reducing or eliminating HCV virus

This abstract tells us:

1) yes - the viral vector is working very well - TT-304 is getting into plenty of liver cells (we already knew this was the case, at least to some extent)

2) yes - shRNA are indeed being generated - I think this is new and very big news

3) don't know - impact on HCV virus is still unknown, at least to us.

So, two steps down, last one to come. But in many ways, the first two steps may have been more major hurdles than the last one.

GLTA

Expand

You have summarised it very well.

BLT Price at posting: 53.5¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

NRX

Noronex joins forces with South32 to look for copper in Namibia

FMG

Andrew Forrest was seemingly possessed by the spirit of hydrogen – now he's cut 700 jobs and canned FFI

Talking Australia's very competitive property landscape: Realty Talks

AI stocks: What to expect in 2024-25

EVN

Evolution shares up 3% on quarterly results for June showing rise in gold production

There are more pages in this discussion • 5 more messages in this thread...

First 18 Last

Add BLT (ASX) to my watchlist